$ADTX News

Aditxt Appoints Jeffrey M. Busch Interom CEO, Effective May 31

Aditxt Q1 EPS $(790.49) Up From $(198.07 thousand) YoY, Sales $12.159K Up From $1.018K YoY

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Aditxt shares are trading lower. Its subsidiary Ignite Proteonomics was included in a study published in the journal npj Precision Oncology.

Aditxt shares are trading lower. Its subsidiary Ignite Proteonomics was included in a study published in the journal npj Precision Oncology.

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Aditxt's Ignite Proteomics Was Featured In NPJ Precision Oncology

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Aditxt Acquires Ignite Proteomics In Transaction Providing 36K Shares Of Aditxt's Newly Designated Series A-2 Convertible Preferred Stock, Representing Aggregate Stated Value Of $36M

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Aditxt Announces 1-For-8 Reverse Stock Split, Effective March 9

Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data

What Sparked Aditxt (ADTX) Stock's 52% After‑Hours Surge?

Aditxt shares are trading lower after the company announced a $20 million offering.

Aditxt Increases At-The-Market Stock Offering Cap To $20M

Aditxt Shares Resume

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times